GlaxoSmithkline Announcement
Posted: June 14th, 2018, 7:05 am
by idpickering
Positive headline results for ViiV GEMINI studies
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
https://www.investegate.co.uk/glaxosmit ... 00043780R/
Re: GlaxoSmithkline Announcement
Posted: June 14th, 2018, 1:42 pm
by monabri
To counter ULVRs drop today, GSK is currently at 1576p ... increased from 1242p on Feb 6th 2018.
(even BT has a smile on it's face!)
Re: GlaxoSmithkline Announcement
Posted: June 14th, 2018, 2:03 pm
by idpickering
monabri wrote:To counter ULVRs drop today, GSK is currently at 1576p ... increased from 1242p on Feb 6th 2018.
(even BT has a smile on it's face!)
Yes a nice 2.3% rise in SP from GSK currently, and BT.A up 2.9%. It's a funny old game this HYP lark.
Ian.
Re: GlaxoSmithkline Announcement
Posted: June 14th, 2018, 5:03 pm
by moorfield
idpickering wrote:Positive headline results for ViiV GEMINI studies
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
https://www.investegate.co.uk/glaxosmit ... 00043780R/
Directorspeak <-> English:
Well it looks like it might work.